Hila Magen

専門分野: Hematologist
35年の経験
話します:
English, Hebrew
オンラインコンサルテーション：利用可能
勤務先: イスラエル, ラマト・ガン, シェバ医療センター
Heads a Multiple Myeloma & Amyloidosis unit; 100+ scientific publications; principal investigator for point-of-care CAR-T programs.
Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Hila Magenとのオンラインコンサルテーション

便利で簡単

100%安全で機密

$650

医師のサービス

調子はいかがですか？

1 の 3

この医師の情報は完全で明確です

強く反対

強く賛成

資格

Dr. Hila Magen, MD

Head, Multiple Myeloma & Amyloidosis Unit – Sheba Medical Center

Leading Expert in Multiple Myeloma, Amyloidosis & Advanced Cellular Therapies

Dr. Hila Magen is a distinguished hemato-oncologist with over 35 years of experience, recognized as one of Israel’s leading experts in the treatment of multiple myeloma and complex plasma cell disorders.

As Head of the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center, she leads a highly specialized program focused on advanced, personalized therapies, including CAR-T cell treatment for high-risk patients.

Areas of Expertise

Multiple Myeloma (Primary Focus)
Comprehensive management of relapsed, refractory, and high-risk myeloma
Amyloidosis & Plasma Cell Disorders
Advanced diagnosis and tailored treatment strategies
Advanced Cellular Therapies
- CAR-T Cell Therapy – principal investigator in innovative, point-of-care CAR-T programs
- Integration of cutting-edge immunotherapies into clinical care
Hematologic Malignancies
Lymphomas and complex blood disorders requiring precision treatment

Clinical Leadership & Innovation

Dr. Magen leads one of the region’s most advanced units dedicated to myeloma and amyloidosis, focusing on:

Personalized, targeted therapies
Early access to innovative treatments and clinical trials
Improving long-term outcomes and quality of life

She is actively involved in developing next-generation CAR-T therapies, offering patients access to some of the most advanced treatment options available worldwide.

International Training & Expertise

Dr. Magen completed advanced training at leading global institutions:

Fellowship in Multiple Myeloma – University of Arkansas for Medical Sciences
Fellowship in Lymphocytic Leukemia – MD Anderson Cancer Center

Leadership & Academic Roles

Head, Multiple Myeloma & Amyloidosis Unit, Sheba Medical Center
Instructor, Tel Aviv University
Active contributor and speaker at international hematology conferences

Research & Recognition

Author of 100+ scientific publications
Contributor to landmark clinical studies in multiple myeloma treatment
Active reviewer in international medical journals

Clinical Approach

Dr. Magen is known for delivering highly personalized and innovative care, focusing on:

Precision diagnosis and tailored treatment plans
Combining standard therapies with cutting-edge innovations
Supporting patients through complex, long-term treatment journeys

Patient-Centered Care

Dr. Magen provides compassionate, expert care, helping patients navigate complex diagnoses with access to world-class treatments, advanced technologies, and multidisciplinary support.

A Leader in Modern Myeloma Treatment

Through her leadership in CAR-T therapy, precision medicine, and advanced myeloma care, Dr. Magen offers patients access to one of the most specialized and advanced treatment programs globally.